用于野生型表皮生长因子受体非小细胞肺癌的表皮生长因子受体抑制剂：用还是不用？ - Suppr

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

作者信息

Jassem Jacek, Dziadziuszko Rafał

机构信息

Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80 211 Gdańsk, Poland.

出版信息

Lancet Oncol. 2013 Sep;14(10):916-7. doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22.

DOI:10.1016/S1470-2045(13)70352-8

PMID:23883923

Abstract

摘要

相似文献

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Lancet Oncol. 2013 Sep;14(10):916-7. doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.

Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18.

Optimising therapy for EGFR-addicted NSCLC: just the start.

Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63.

Targeting EGFR in non-small-cell lung cancer.

N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113.

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60193-8.

3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.

引用本文的文献

Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec.

A rotamer relay information system in the epidermal growth factor receptor-drug complexes reveals clues to new paradigm in protein conformational change.

Comput Struct Biotechnol J. 2021 Sep 27;19:5443-5454. doi: 10.1016/j.csbj.2021.09.026. eCollection 2021.

Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Front Oncol. 2019 Aug 23;9:800. doi: 10.3389/fonc.2019.00800. eCollection 2019.

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Transl Lung Cancer Res. 2015 Aug;4(4):465-74. doi: 10.3978/j.issn.2218-6751.2015.07.17.

MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer.

Tumour Biol. 2015 Aug;36(8):5785-90. doi: 10.1007/s13277-015-3247-z. Epub 2015 Feb 26.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer.

Tumour Biol. 2014 Jul;35(7):6673-8. doi: 10.1007/s13277-014-1850-z. Epub 2014 Apr 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

作者信息

机构信息

出版信息

相似文献

引用本文的文献